Publication & Citation Trends
Publications
0 total
Abstract 652: Exploiting PRMT5, a metabolic and epigenetic regulator, as a novel therapeutic target in mantle cell lymphoma
Cited by 0
Semantic Scholar
Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma OA
Cited by 9
Semantic Scholar
Tumor Microenvironment Molecular Signatures That Define Therapeutic Resistance in Mantle Cell Lymphoma OA
Cited by 4
Semantic Scholar
Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial OA
Cited by 13
Semantic Scholar
Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL
Cited by 2
Semantic Scholar
Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma OA
Cited by 20
Semantic Scholar
Molecular Profiling plus In Vitro and In Vivo Drug Efficacy Analyses Identifies Novel Treatments to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Cited by 0
Semantic Scholar
PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells OA
Cited by 59
Semantic Scholar
Research Topics
Lymphoma Diagnosis and Treatment
(2)
Chronic Lymphocytic Leukemia Research
(2)
Galectins and Cancer Biology
(2)
Affiliations
The University of Texas MD Anderson Cancer Center